Cerus Corporation (CERS) Stock: Gaining Big On Solid Clinical Results


What We’re Seeing From The Stock 

As investors, one of the first things that we learn is that the news moves the market. In this particular case, the news released by Cerus Corporation proved to be overwhelmingly positive, leading to excitement among investors and sending the stock screaming for the top. As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:20), CERS is trading at $5.61 per share after a gain of $1.28 per share or 29.56% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on CERS. In particular, we’re interested in following the company’s release of the full data from this key Phase 3 clinical trial as well as their work to obtain CE Mark approval, as well as other regulatory approvals around the world. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!


Please enter your comment!
Please enter your name here